Working... Menu
Trial record 21 of 37 for:    Developmental Disabilities | ( Map: Oregon, United States )

A Trial of CM-AT in Children With Autism (CM-AT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00881452
Recruitment Status : Completed
First Posted : April 15, 2009
Last Update Posted : April 19, 2018
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism.

Condition or disease Intervention/treatment Phase
Autism Drug: CM-AT Drug: Placebo Phase 3

Detailed Description:
Autism is currently a significant cause of disability in the pediatric population. Treatment is based upon the observation that many children with autism do not digest protein. CM-AT is a proprietary enzyme that is designed as a powder taken three times a day.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 182 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Randomized Double Blind Placebo Controlled Trial of CM-AT in Children With Autism
Study Start Date : May 2009
Actual Primary Completion Date : June 2011
Actual Study Completion Date : September 2011

Arm Intervention/treatment
Active Comparator: CM-AT
CM-AT (Luminenz-AT)- 900mg CM-AT, pancreatic enzyme concentrate (720mg)
Drug: CM-AT
Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
Other Name: 900mg CM-AT (pancreatic enzyme concentrate, 720mg

Placebo Comparator: Placebo
Placebo 900mg (Sucanate (98% w/w), Citric Acid (2% w/w)
Drug: Placebo
Single unit dose powder of non-active substance administered 3 times per day for 90 days
Other Name: 900mg (Sucanate (98% w/w), Citric Acid (2% w/w)

Primary Outcome Measures :
  1. Evidence of changes in behavior scales associated with the core symptoms of autism [ Time Frame: Baseline, 14 days, 30 days, 60 days, 90 days ]

Secondary Outcome Measures :
  1. Other key measures of behavior and quality of life associated with autism [ Time Frame: Baseline, 14 days, 30 days, 60 days, 90 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years to 8 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meets the current Diagnostic and Statistical Manual for Mental Disorders (DSM-IV-TR) diagnostic criteria for autistic disorder (AD)

Exclusion Criteria:

  • Patient weighing < 11kg (24.2 lbs.)
  • Demonstrated previous allergy to porcine (pork) products
  • Previous history of severe head trauma or stroke, seizure within one year of entering study or uncontrolled systemic disease
  • Diagnosis of: HIV, cerebral palsy, endocrine disorder, pancreatic disease
  • Within 30 days of starting the study, certain supplementation, chelation or dietary restriction (a 30 day washout period would be required for inclusion)
  • Use of of any stimulant medication must be discontinued 5 days prior to entering the study.
  • Subject must have a stable dose of SSRI's for at least 30 days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00881452

Layout table for location information
United States, Arizona
Southwest Autism Research and Resource Center
Phoenix, Arizona, United States, 85006
United States, California
University of California, Davis, M.I.N.D. Institute
Sacramento, California, United States, 95817
University of California, San Francisco
San Francisco, California, United States, 94143
Neuropsychiatric Research Center of Orange County
Santa Ana, California, United States, 92701
United States, Florida
Lake Mary Pediatrics
Orange City, Florida, United States, 32763
United States, Georgia
Institute for Behavioral Medicine
Smyrna, Georgia, United States, 30080
United States, Illinois
Alexian Brothers Center for Psychiatric Research
Hoffman Estates, Illinois, United States, 60169
United States, Louisiana
Louisiana State University Health Science Center
Shreveport, Louisiana, United States, 71103
United States, New Jersey
Saint Peters University Hospital
New Brunswick, New Jersey, United States, 08901
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27514
United States, Ohio
Ohio State University
Columbus, Ohio, United States, 43210
United States, Oklahoma
Oklahoma University Child Study Center
Oklahoma City, Oklahoma, United States, 73117
United States, Oregon
Cyn3rgy Research
Gresham, Oregon, United States, 97030
United States, Pennsylvania
Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Drexel University
Philadelphia, Pennsylvania, United States, 19124
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15260
United States, Texas
University of Texas, Houston
Houston, Texas, United States, 77054
United States, Utah
Westside Medical
Clinton, Utah, United States, 84015
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Eugene Arnold, MD MEd. Nisonger Center Ohio State University


Layout table for additonal information
Responsible Party: Curemark Identifier: NCT00881452     History of Changes
Other Study ID Numbers: 00101
First Posted: April 15, 2009    Key Record Dates
Last Update Posted: April 19, 2018
Last Verified: April 2018

Keywords provided by Curemark:

Additional relevant MeSH terms:
Layout table for MeSH terms
Child Development Disorders, Pervasive
Autistic Disorder
Autism Spectrum Disorder
Neurodevelopmental Disorders
Mental Disorders
Citric Acid
Sodium Citrate
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action